Two Dose Regimens of Nifedipine for Management of Preterm Labor: A Randomized Controlled Trial

ABSTRACT

We compared two dose regimens of tocolytic oral nifedipine. Women with singleton pregnancies admitted in preterm labor (24 to 34 weeks) were randomized to high-dose (HD) nifedipine (n = 49; 20 mg loading dose, repeated in 30 minutes, daily 120 to 160 mg slow-release nifedipine for 48 hours followed by 80 to 120 mg daily until 36 weeks) or low-dose (LD) nifedipine (n = 53; 10 mg, up to four doses every 15 minutes, daily 60 to 80 mg slow-release nifedipine for 48 hours followed by 60 mg daily until 36 weeks). Uterine quiescence at 48 hours (primary outcome); delivery at 48 hours, 34 and 37 weeks; and recurrent preterm labor were similar. Gestational age at delivery was higher in HD (36.0 ± 2.8 versus 34.7 ± 3.7 weeks, p = 0.049). Rescue treatment was needed more in LD (24.5 versus 50.9%, odds ratio = 0.3; 95% confidence interval 0.1 to 0.7). Maternal adverse effects, birth weight, intensive care nursery admission, and composite neonatal morbidity were similar. However, neonatal mechanical ventilation was needed less and nursery stay was shorter in HD. HD nifedipine does not seem to have an advantage over LD in achieving uterine quiescence at 48 hours. Further studies should address the optimal dose and formulation of tocolytic nifedipine.

KEYWORDS

Nifedipine - preterm labor - tocolysis - two dose regimens

REFERENCES

• 1 Martin J A, Hamilton B E, Sutton P D et al.. Births: final data for 2005.  Natl Vital Stat Rep. 2007;  56 1-103
• 2 Lewis D F. Magnesium sulfate: the first-line tocolytic.  Obstet Gynecol Clin North Am. 2005;  32 485-500
• 3 Crowther C A, Hiller J E, Doyle L W. Magnesium sulphate for preventing preterm birth in threatened preterm labour.  Cochrane Database Syst Rev. 2002;  CD001060
• 4 Nassar A H, Sakhel K, Maarouf H, Naassan G R, Usta I M. Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis.  Acta Obstet Gynecol Scand. 2006;  85 1099-1103
• 5 Grimes D A, Nanda K. Magnesium sulfate tocolysis: time to quit.  Obstet Gynecol. 2006;  108 986-989
• 6 Mittendorf R, Dambrosia J, Pryde P G et al.. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants.  Am J Obstet Gynecol. 2002;  186 1111-1118
• 7 Anotayanonth S, Subhedar N V, Garner P, Neilson J P, Harigopal S. Betamimetics for inhibiting preterm labour.  Cochrane Database Syst Rev. 2004;  CD004352
• 8 Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour.  Cochrane Database Syst Rev. 2005;  CD004452
• 9 King J F, Flenady V J, Papatsonis D N, Dekker G A, Carbonne B. Calcium channel blockers for inhibiting preterm labour.  Cochrane Database Syst Rev. 2003;  CD002255
• 10 Duley L M. Tocolytic drugs for women in preterm labour. RCOG (Royal College of Obstetricians and Gynaecologists, UK) Guideline No 1B. London; RCOG 2002
• 11 Carr D B, Clark A L, Kernek K, Spinnato J A. Maintenance oral nifedipine for preterm labor: a randomized clinical trial.  Am J Obstet Gynecol. 1999;  181 822-827
• 12 PATH, World Health Organization, United Nations Population Fund .Essential medicines for reproductive health: guiding principles for their inclusion on national medicines lists. Seattle, WA; PATH 2006 http://Available at www.who.int/reproductive-health/publications/essential_medicines/emls_guidingprinciples.pdf
• 13 Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis.  Obstet Gynecol. 2001;  97 840-847
• 14 Glock J L, Morales W J. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study.  Am J Obstet Gynecol. 1993;  169 960-964
• 15 Papatsonis D N, van Geijn H P, Bleker O P, Ader H J, Dekker G A. Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis.  Int J Gynaecol Obstet. 2003;  82 5-10
• 16 van Veen A J, Pelinck M J, van Pampus M G, Erwich J J. Severe hypotension and fetal death due to tocolysis with nifedipine.  BJOG. 2005;  112 509-510
• 17 Ferguson 2nd J E, Schutz T, Pershe R, Stevenson D K, Blaschke T. Nifedipine pharmacokinetics during preterm labor tocolysis.  Am J Obstet Gynecol. 1989;  161 1485-1490
• 18 Guclu S, Saygili U, Dogan E, Demir N, Baschat A A. The short-term effect of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms.  Ultrasound Obstet Gynecol. 2004;  24 761-765
• 19 Economy K E, Abuhamad A Z. Calcium channel blockers as tocolytics.  Semin Perinatol. 2001;  25 264-271
• 20 van Geijn H P, Lenglet J E, Bolte A C. Nifedipine trials: effectiveness and safety aspects.  BJOG. 2005;  112 79-83
• 21 Nassar A H, Ghazeeri G, Usta I M. Nifedipine-associated pulmonary complications in pregnancy.  Int J Gynaecol Obstet. 2007;  97 148-149
• 22 Verhaert D, Van Acker R. Acute myocardial infarction during pregnancy.  Acta Cardiol. 2004;  59 331-339
• 23 Parasuraman R, Gandhi M M, Liversedge N H. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion.  BJOG. 2006;  113 844-845
• 24 Ugwumadu A. Nifedipine-tocolysis-associated atrial fibrillation responds to DC cardioversion.  BJOG. 2007;  114 236-237
• 25 Taslimi M M, Sibai B M, Amon E, Taslimi C K, Herrick C N. A national survey on preterm labor.  Am J Obstet Gynecol. 1989;  160 1352-1357